XML 106 R66.htm IDEA: XBRL DOCUMENT v2.4.1.9
ACQUISITIONS (Details) (USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2014
Dec. 31, 2013
Acquisition [Line Items]      
Impairment charge for BMS-986094 intangible asset $ 1,830us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill    
Identifiable net assets and liabilities assumed - Goodwill   7,027us-gaap_Goodwill 7,096us-gaap_Goodwill
iPierian, Inc. [Member]      
Acquisition [Line Items]      
Asset acquisition upfront payment   175bmy_Assetacquisitionpayment
/ us-gaap_BusinessAcquisitionAxis
= bmy_IPierianInc.Member
 
Contingent and regulatory milestone payments   550bmy_ContingentandRegulatoryMilestonePayments
/ us-gaap_BusinessAcquisitionAxis
= bmy_IPierianInc.Member
 
Asset acquisition upfront payment net of tax   148bmy_Assetacquisitionupfrontpaymentnetoftax
/ us-gaap_BusinessAcquisitionAxis
= bmy_IPierianInc.Member
 
Deferred tax assets related to asset acquisition   27us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= bmy_IPierianInc.Member
 
Amylin Pharmaceuticals, Inc. [Member]      
Acquisition [Line Items]      
Acquisition costs 29us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Cash 179us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Marketable securities 108us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Inventory 173us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Property, plant and equipment 742us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Developed technology rights 6,340us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - In-process research and development 120us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Other assets 136us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Debt obligations (2,020)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Other liabilities (339)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Deferred income taxes (1,068)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Total identifiable net assets 4,371us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Goodwill 847us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Identifiable net assets and liabilities assumed - Total consideration transferred 5,218us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Cash paid to outstanding common stockholders of the acquiree 5,100bmy_CashPaidToOutstandingCommonStockholders
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Cash paid to option and restricted stock unit holders 219bmy_CashPaidToOptionAndRestrictedStockUnitHolders
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Stock-based compensation expense 94us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
/ us-gaap_BusinessAcquisitionAxis
= bmy_AmylinPharmaceuticalsIncMember
   
Inhibitex, Inc. [Member]      
Acquisition [Line Items]      
Acquisition costs 12us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Impairment charge for BMS-986094 intangible asset 1,800us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Cash 46us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Marketable securities 17us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - In-process research and development 1,875us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Debt obligations (23)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Other liabilities (10)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Deferred income taxes (579)us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Total identifiable net assets 1,326us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Goodwill 1,213us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember
   
Identifiable net assets and liabilities assumed - Total consideration transferred $ 2,539us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= bmy_InhibitexIncMember